Welcome to our dedicated page for UPTD news (Ticker: uptd), a resource for investors and traders seeking the latest updates and insights on UPTD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect UPTD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of UPTD's position in the market.
Summary not available.
Summary not available.
On October 3, 2022, Estrella Biopharma announced a definitive business combination agreement with TradeUP Acquisition Corp. (NASDAQ: UPTD) dated September 30, 2022. This merger will result in Estrella becoming publicly listed as Estrella Immunopharma, Inc. Estrella specializes in CD19-targeted ARTEMIS®️ T-cell therapies for blood cancers and solid tumors, with lead candidates EB103 and EB104. The transaction anticipates a pro forma equity valuation of approximately $398.5 million, with TradeUP's shareholders retaining about 11.1% ownership post-merger. The deal is expected to close in the first half of 2023, pending approvals.